Biomarker analyses of second-line ramucirumab in patients with advanced gastric cancer from RAINBOW, a global, randomized, double-blind, phase 3 study.
暂无分享,去创建一个
J. Ajani | E. Van Cutsem | G. Bodoky | Z. Wainberg | D. Cunningham | D. Ferry | K. Muro | A. Ohtsu | S. Cascinu | S. Al-Batran | S. Wijayawardana | A. Sobrero | R. Hozak | S. Melemed | S. Oh
[1] E. Van Cutsem,et al. Analysis of angiogenesis biomarkers for ramucirumab efficacy in patients with metastatic colorectal cancer from RAISE, a global, randomized, double-blind, phase III study , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.
[2] M. Ychou,et al. 473OThree versus six months’ adjuvant oxaliplatin-based chemotherapy for patients with stage III colon cancer: Per-protocol, subgroups and long-lasting neuropathy results , 2017 .
[3] E. Van Cutsem,et al. Evaluation of Angiopoietin-2 as a biomarker in gastric cancer: results from the randomised phase III AVAGAST trial , 2016, British Journal of Cancer.
[4] S. Tjulandin,et al. Second-line treatment of metastatic gastric cancer: Current options and future directions. , 2015, World journal of gastroenterology.
[5] Naotoshi Sugimoto,et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. , 2014, The Lancet. Oncology.
[6] P. Hegde,et al. Comprehensive reassessment of plasma VEGFA (pVEGFA) as a candidate predictive biomarker for bevacizumab (Bv) in 13 pivotal trials (seven indications). , 2014 .
[7] C. Fuchs,et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial , 2014, The Lancet.
[8] D. Cunningham,et al. Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial. , 2014, The Lancet. Oncology.
[9] E. Mochiki,et al. C-reactive protein as a significant prognostic factor for stage IV gastric cancer patients. , 2013, Anticancer research.
[10] M. Detmar,et al. VEGF-C and VEGF-D blockade inhibits inflammatory skin carcinogenesis. , 2013, Cancer research.
[11] P. Carmeliet,et al. Markers of response for the antiangiogenic agent bevacizumab. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] Chang-qing Yang,et al. Overexpression of both VEGF-A and VEGF-C in gastric cancer correlates with prognosis, and silencing of both is effective to inhibit cancer growth. , 2013, International journal of clinical and experimental pathology.
[13] Chibo Liu,et al. Identification of serum amyloid A in the serum of gastric cancer patients by protein expression profiling. , 2012, Oncology letters.
[14] Joon-Oh Park,et al. Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] A. Hinke,et al. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). , 2011, European journal of cancer.
[16] Z. Ye,et al. Expression of Hepatocyte Growth Factor and Basic Fibroblast Growth Factor as Prognostic Indicators in Gastric Cancer , 2009, Anatomical record.
[17] G. Neufeld,et al. Pro-angiogenic cytokines and their role in tumor angiogenesis , 2006, Cancer and Metastasis Reviews.
[18] J. Haerting,et al. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] D. Teti,et al. Serum levels of interleukin 1β, interleukin 8 and tumour necrosis factor α as markers of gastric cancer , 2006 .
[20] L. Ellis,et al. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] S. Stacker,et al. Focus on lymphangiogenesis in tumor metastasis. , 2005, Cancer cell.
[22] K. Shirouzu,et al. VEGF significance in peritoneal recurrence from gastric cancer , 2005, Gastric Cancer.
[23] C. Fondevila,et al. p53 and VEGF expression are independent predictors of tumour recurrence and survival following curative resection of gastric cancer , 2004, British Journal of Cancer.
[24] N. Yang,et al. Tumor-derived vascular endothelial growth factor up-regulates angiopoietin-2 in host endothelium and destabilizes host vasculature, supporting angiogenesis in ovarian cancer. , 2003, Cancer research.